Chiron's Sean Lance to Succeed Bill Rutter as Chairman of the Board; Raymond Breu of Novartis Elected to Board.EMERYVILLE, Calif.--(BW HealthWire)--May 13, 1999-- Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. (Nasdaq:CHIR CHIR Chiricahua National Monument (US National Park Service) ), today announced that Sean Lance, the company's president and chief executive officer, will be named chairman of the board succeeding William (Bill) J. Rutter, Ph.D. The company also announced that Raymund Breu, Ph.D., Novartis AG's chief financial officer, has been elected to Chiron's board of directors, replacing Alex Krauer, Ph.D., Novartis' former chairman. Sean Lance, who joined Chiron from Glaxo Wellcome plc where he was chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. , will chair the board, effective May 14, 1999. Dr. Rutter, one of the company's founders and its chairman since its inception in 1981, will remain on the board of directors and act as an advisor to Mr. Lance. "I am pleased with the progress that Chiron has made under Sean's leadership. It is now appropriate to complete the management transition by appointing Sean chairman," said Dr. Rutter. "I look forward to supporting Sean and the company in any way that I can." "As the founding chairman, Bill played an integral role in Chiron's numerous scientific discoveries and commercial successes," said Sean Lance. "The opportunities that Chiron enjoys today are in large part due to Bill's vision and his commitment to advancing science. His continued counsel will be an ongoing benefit to me and to the organization." Dr. Breu, a member of Novartis' executive committee, is responsible for all of the financial activities of the Novartis Group worldwide. He assumed these responsibilities upon the formation of Novartis in 1996 when Ciba-Geigy ltd. merged with Sandoz, creating one of the largest international pharmaceutical companies. Prior to that, Dr. Breu spent more than 20 years at Sandoz holding several senior management positions including serving as the head of group finance and as a member of its executive committee. Dr. Breu graduated from the Swiss Federal Institute of Technology The Swiss Federal Institute of Technology may refer to one of two institutes of higher education in Switzerland:
"Dr. Breu's broad financial experience with complex pharmaceutical organizations will be an important resource as we continue to streamline our business operations Business operations are those activities involved in the running of a business for the purpose of producing value for the stakeholders. Compare business processes. The outcome of business operations is the harvesting of value from assets and advance our products in development," said Mr. Lance. "On behalf of the board and the management team, I also thank Dr. Krauer for his contributions to Chiron including his valuable insights and important commercial perspective." Chiron Corporation, headquartered in Emeryville, California Emeryville is a small city located in Alameda County, California , in the United States. It is located in a corridor between the cities of Berkeley and Oakland, extending to the shore of San Francisco Bay. , is a leading biotechnology company that participates in three global healthcare markets: biopharmaceuticals, blood testing and vaccines. The company is applying a broad and integrated scientific approach to the development of innovative products for preventing and treating cancer, infectious diseases infectious diseases: see communicable diseases. , and cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . This approach is supported by research strengths in recombinant proteins Since human recombinants have replaced the animal version in human therapeutics, the prefix of "rh" for "human recombinant" appears less and less in the literature Human recombinants that replaced animal or harvested from human types |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion